Skip to main content
All lobbying filings

AMNEAL PHARMACEUTICALS

Lobbying for AMNEAL PHARMACEUTICALS · Pharmaceutical company

 Filing 1st Quarter - Report
1st Quarter (Jan 1 - Mar 31) 2026 · New Jersey · House · Senate · $190,000.00 expenses · posted Apr 20, 2026

Official filing document

 Lobbying activity 1
Health Issues

Addressing drug shortages and enhancing domestic production of critical medicines Issues and proposed legislation related to long-term sustainability of access for patients to generic and biosimilar medicines, including but not limited to pharmaceutical supply chain security, drug shortages, biosimilar interchangeability, and PBM reform Issues related to Medicaid Generics Penalty Issues related to possible drug shortage of levothyroxine capsules Issues related to tariffs Appropriations for increasing domestic manufacturing of generic medicines Issues related to NDAA

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem